Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Baricitinib phosphate (INCB028050) 是一种选择性的,可口服的 JAK1/JAK2抑制剂,IC50值分别为 5.9 和 5.7 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 278 | 现货 | ||
10 mg | ¥ 393 | 现货 | ||
25 mg | ¥ 659 | 现货 | ||
50 mg | ¥ 978 | 现货 | ||
100 mg | ¥ 1,470 | 现货 | ||
500 mg | ¥ 4,150 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 349 | 现货 |
产品描述 | Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor. |
靶点活性 | JAK2:5.7 nM, JAK1:5.9 nM |
体外活性 | In cell-based assays, Baricitinib (INCB028050) proves to be a potent inhibitor of JAK signaling and function. In PBMCs, Baricitinib inhibits IL-6-stimulated phosphorylation of the canonical substrate STAT3 (pSTAT3) and subsequent production of the chemokine MCP-1 with IC50 values of 44 nM and 40 nM, respectively. In isolated naive T-cells, INCB028050 also inhibits pSTAT3 stimulated by IL-23 (IC50=20 nM). Importantly, this inhibition prevented the production of two pathogenic cytokines (IL-17 and IL-22) produced by Th17 cells-a subtype of helper T cells with demonstrable inflammatory and pathogenic properties-with an IC50 value of 50 nM. In stark contrast, the structurally similar but ineffective JAK1/2 inhibitors INCB027753 and INCB029843 has no significant effect in any of these assays systems when tested at concentrations up to 10 μM[1]. |
体内活性 | Baricitinib (INCB028050) treatment, compares with vehicle, inhibits the increase in hind paw volumes during the 2 wk of treatment by 50% at a dose of 1 mg/kg and >95% at doses of 3 or 10 mg/kg. Because baseline paw volume measurements are taken on treatment day 0—in animals with significant signs of disease-it is possible to have >100% inhibition in animals showing marked improvement in swelling[1]. Baricitinib (0.7 mg/day) treated mice exhibits substantially reduced inflammation as assessed by H&E staining, reduced CD8 infiltration, and reduced MHC class I and class II expression when compared with vehicle-control treated mice. CD8+NKG2D+ cells, critical effectors of disease in murine and human alopecia areata (AA), are greatly diminished in Baricitinib treated mice compare with vehicle control treated mice[2]. |
激酶实验 | Enzyme assays are performed using a homogeneous time-resolved fluorescence assay with recombinant epitope tagged kinase domains (JAK1, 837-1142; JAK2, 828-1132; JAK3, 718-1124; Tyk2, 873-1187) or full-length enzyme (cMET and Chk2) and peptide substrate. Each enzyme reaction is performed with or without test compound (11-point dilution), JAK, cMET, or Chk2 enzyme, 500 nM (100 nM for Chk2) peptide, ATP (at the Km specific for each kinase or 1 mM), and 2.0% DMSO in assay buffer. The calculated IC50 value is the compound concentration required for inhibition of 50% of the fluorescent signal. Additional kinase assays are performed at Cerep using standard conditions at 200 nM. Enzymes tested included: Abl, Akt1, AurA, AurB, CDC2, CDK2, CDK4, CHK2, c-kit, EGFR, EphB4, ERK1, ERK2, FLT-1, HER2, IGF1R, IKKα, IKKβ, JNK1, Lck, MEK1, p38α, p70S6K, PKA, PKCα, Src, and ZAP70[1]. |
细胞实验 | Baricitinib(INCB 028050) is dissolved in stock solutions, and then diluted with appropriate media before use[1]. Human PBMCs are isolated by leukapheresis followed by Ficoll-Hypaque centrifugation. For the determination of IL-6-induced MCP-1 production, PBMCs are plated at 3.3×105 cells per well in RPMI 1640+10% FCS in the presence or absence of various concentrations of INCB028050 (1 nM, 10 nM, 100 nM, 1 μM, and 10 μM). Following preincubation with compound for 10 min at room temperature, cells are stimulated by adding 10 ng/mL human recombinant IL-6 to each well. Cells are incubated for 48 h at 37°C, 5% CO2. Supernatants are harvested and analyzed by ELISA for levels of human MCP-1. The ability of INCB028050 to inhibit IL-6-induced secretion of MCP-1 is reported as the concentration required for 50% inhibition (IC50). Proliferation of Ba/F3-TEL-JAK3 cells is performed over 3 d using Cell-Titer Glo[1]. |
别名 | Baricitinib Phosphate, LY3009104, 磷酸巴瑞克替尼, INCB-028050 phosphate, LY-3009104 phosphate, INCB028050 |
分子量 | 469.41 |
分子式 | C16H20N7O6PS |
CAS No. | 1187595-84-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 200 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1303 mL | 10.6517 mL | 21.3033 mL | 53.2583 mL |
5 mM | 0.4261 mL | 2.1303 mL | 4.2607 mL | 10.6517 mL | |
10 mM | 0.213 mL | 1.0652 mL | 2.1303 mL | 5.3258 mL | |
20 mM | 0.1065 mL | 0.5326 mL | 1.0652 mL | 2.6629 mL | |
50 mM | 0.0426 mL | 0.213 mL | 0.4261 mL | 1.0652 mL | |
100 mM | 0.0213 mL | 0.1065 mL | 0.213 mL | 0.5326 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Baricitinib phosphate 1187595-84-1 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors Tyrosine Kinases JAK LY-3009104 Baricitinib Phosphate inhibit LY3009104 INCB-028050 Phosphate Janus kinase 磷酸巴瑞克替尼 Baricitinib LY 3009104 Phosphate INCB-028050 INCB-028050 phosphate LY-3009104 Phosphate Inhibitor LY 3009104 LY-3009104 phosphate Baricitinib Phosphate INCB 028050 Phosphate INCB028050 INCB028050 Phosphate LY3009104 Phosphate INCB 028050 inhibitor